A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus
Clinical trial NCT04682873 · COMPLETED
Trial details
- NCT number
- NCT04682873
- Sponsor
- Joint Stock Company "Farmak"
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-05-15
- Primary completion
- 2021-03-26
- Enrollment
- 592
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.